Previous 10 | Next 10 |
OpGen (NASDAQ: OPGN ) +74% on being beneficiaries related to COVID-19. More news on: OpGen, Inc., BioNTech SE, Neon Therapeutics, Inc., Stocks on the move, , Read more ...
ZAGG (NASDAQ: ZAGG ) -44% after ending strategic review with no deal and Q4 earnings. More news on: ZAGG Inc, Sasol Limited, Party City Holdco Inc., Stocks on the move, , Read more ...
Penny Stocks To Watch As Coronavirus Cases Rise How bad is the spread coronavirus? It’s so bad that a conference held to discuss it was canceled because of it. The Council on Foreign Relations has canceled a roundtable called “Doing Business Under Coronavirus” scheduled fo...
Tiziana Life Sciences PLC (NASDAQ: TLSA ) +162% on potential coronavirus treatment . More news on: Tiziana Life Sciences PLC, Phio Pharmaceuticals Corp., Inovio Pharmaceuticals, Inc., Stocks on the move, , Read more ...
MARLBOROUGH, Mass. and MARTINSRIED/ MUNICH , March 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platfo...
MARLBOROUGH, Mass. , Feb. 13, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced t...
Gainers : Rexahn Pharmaceuticals (NASDAQ: REXN ) +85% . More news on: Rexahn Pharmaceuticals, Inc., Sprint Corporation, Genprex, Inc., Stocks on the move, , Read more ...
Phio Pharmaceuticals (NASDAQ: PHIO ) is down 52% premarket after pricing its public offering of an aggregate of 2M units at $4.00 per unit, for gross proceeds of ~$8M. More news on: Phio Pharmaceuticals Corp., Healthcare stocks news, Stocks on the move, , Read more ...
MARLBOROUGH, Mass. , Feb. 11, 2020 /PRNewswire/ --- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced the p...
MARLBOROUGH, Mass. , Feb. 10, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced that i...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...